-
Functional Areas
- Audit and Investigations
-
Capacity development and transition, strengthening systems for health
- A Strategic Approach to Capacity Development
- Capacity Development and Transition - Lessons Learned
- Capacity development and Transition Planning Process
- Capacity Development and Transition
- Capacity Development Objectives and Transition Milestones
- Capacity Development Results - Evidence From Country Experiences
- Functional Capacities
- Interim Principal Recipient of Global Fund Grants
- Legal and Policy Enabling Environment
- Overview
- Resilience and Sustainability
- Transition
-
Financial Management
- CCM Funding
- Grant Closure
- Grant Implementation
- Grant-Making and Signing
- Grant Reporting
- Import duties and VAT / sales tax
- Overview
- Sub-recipient Management
-
Grant closure
- Overview
-
Steps of Grant Closure Process
- 1. Global Fund Notification Letter 'Guidance on Grant Closure'
- 2. Preparation and Submission of Grant Close-Out Plan and Budget
- 3. Global Fund Approval of Grant Close-Out Plan
- 4. Implementation of Close-Out Plan and Completion of Final Global Fund Requirements (Grant Closure Period)
- 5. Operational Closure of Project
- 6. Financial Closure of Project
- 7. Documentation of Grant Closure with Global Fund Grant Closure Letter
- Terminology and Scenarios for Grant Closure Process
- Human resources
- Human rights, key populations and gender
-
Legal Framework
- Agreements with Sub-recipients
- Agreements with Sub-sub-recipients
- Amending Legal Agreements
- Implementation Letters and Performance Letters
- Language of the Grant Agreement and other Legal Instruments
- Legal Framework for Other UNDP Support Roles
- Other Legal and Implementation Considerations
- Overview
- Project Document
- Signing Legal Agreements and Requests for Disbursement
-
The Grant Agreement
- Grant Confirmation: Conditions Precedent (CP)
- Grant Confirmation: Conditions
- Grant Confirmation: Face Sheet
- Grant Confirmation: Schedule 1, Integrated Grant Description
- Grant Confirmation: Schedule 1, Performance Framework
- Grant Confirmation: Schedule 1, Summary Budget
- Grant Confirmation: Special Conditions (SCs)
- Grant Confirmation
- UNDP-Global Fund Grant Regulations
-
Monitoring and Evaluation
- Differentiation Approach
- Monitoring and Evaluation Components of Funding Request
- M&E Components of Grant Implementation
- Monitoring and Evaluation Components of Grant Making
- Overview
- Principal Recipient Start-Up
-
Health Product Management
- Compliance with the Global Fund requirements
- Distribution
- Inspection and Receipt
- International freight, transit requirements and use of INCOTERMS
- Inventory Management
- Overview - Health Product Management
- Pharmacovigilance
- Product Selection
- Quality monitoring of health products
- Quantification and Forecasting
- Rational use
- Risk Management for PSM of health products
-
Sourcing and regulatory aspects
- Development of List of Health Products
- Development of the Health Procurement Action Plan (HPAP)
- Global Health Procurement Center (GHPC)
- Guidance on donations of health products
- Health Procurement Architecture
- Local Procurement of health products
- Other Elements of the UNDP Procurement Architecture
- Procurement of non-pharmaceutical Health Products
- Procurement of Pharmaceutical Products
- Submission of GHPC CO Procurement Request Form
- Storage
- Supply Planning of Health Products
- UNDP Health PSM Roster
- Waste management
- Grant Reporting
-
Risk Management
- Introduction to Risk Management
- Overview
- Risk management in crisis settings
-
Risk Management in the Global Fund
- Additional Safeguard Policy
- Challenging Operating Environment (COE) Policy
- Global Fund Review of Risk Management During Grant Implementation
- Global Fund Risk Management Framework
- Global Fund Risk Management Requirements During Funding Request
- Global Fund Risk Management Requirements for PRs
- Local Fund Agent
- Risk management in UNDP
- Risk Management in UNDP-managed Global Fund projects
- UNDP Risk Management Process
- Sub-Recipient Management
Procurement of Pharmaceutical Products
Practice PointerTo identify the channel to use for sourcing health products, please refer to the Health Procurement Architecture. If you are unable to find the product category under the Health Procurement Architecture, please contact the GHPC Health Procurement Services Team, based in UNDP, Copenhagen.
The UNDP Bureau for Management Services (BMS) Office of Procurement (OP) has established multiple Long-Term Agreements (LTAs) with commercial partners (manufacturers & suppliers/wholesalers) for the supply of the medicines that meet the minimum UNDP quality assurance requirements.
UNDP has LTAs established for adult antiretroviral (ARV) medicines, adult and pediatric first-line anti-TB medicines, all malaria medicines, medicines for managing STIs and opportunistic infections, medicines to treat Hepatitis B and Hepatitis C, as well as a range of other essential medicines and medicines for treating non-communicable disease (NCDs), such as diabetes, hypertension, and cancers.
All LTAs for health products that have been established centrally by the GHPC are closed and are only available for use by the GHPC HPS team.
The GHPC procurement team in Copenhagen conducts the procurement process on behalf of the CO for Global Fund programmes and for other health programmes.
Practice PointerGHPC processes the requests for medicines semesterly, based on the consolidated demands of HPAP validated items.
Where urgent needs are identified outside of this schedule, the UNDP CO can send the request to HPS team focal point with copy to the GFPHST HPM focal point.
Beyond these UNDP LTAs, UNDP engages the services of other UN agencies to support procurement of pediatric ARV medicines and medicines to treat drug-resistant TB.
ARV medicines: pediatric formulations
UNDP has a Memorandum of Understanding (MoU) with the United Nations Children’s Fund (UNICEF) Supply Division for sourcing pediatric antiretroviral medicines. For product selection, please refer to UNICEF online catalogue.
The COs/Project Management Units (PMUs) can submit the request for cost estimate to UNICEF psid@unicef.org by following the guideline here.
Drug-resistant tuberculosis medicines: all formulations
In light of the specificities of drug-resistant TB medicines, all TB medicines to treat drug-resistant TB must be procured through the Stop TB Partnership’s Global Drug Facility (GDF). UNDP COs source these medicines through UNOPS/GDF Stop TB Partnership by piggybacking their LTA with the procurement agency (i.e., iPlus Solutions). A copy of the agreement is available here. If GDF changes its procurement agents based on the outcome of the competitive procurement process, UNDP COs will be informed accordingly.
To be consistent with the policies of other international funding sources, all procurement of medicines to treat multi-drug resistant TB (MDR-TB), which is financed by the Global Fund, must be conducted through the Stop TB Partnership’s GDF. This is in adherence with the Global Fund 13th Board Decision of 2006. A step by step guideline to process the request through GDF is available here and here. For product selection of SLD, please refer to GDF Product Catalog | Stop TB Partnership.
Practice PointerWhere UNDP relies on other United Nations agencies to assist with the procurement of specific categories of health products and where there are specific cases in which these UN agencies are unable to provide support, alternative arrangements will need to be made to procure products which are compliant with UNDP quality assurance requirements. In this case, the GHPC Health Procurement Services team will need to be informed, and can advise the CO on how to proceed.
Loading resources
